UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Summary
This observational study will evaluate an assay using a patient’s own biopsy or resected tumor tissue to assess tissue response to various therapeutic agents.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
DCC-2618 is an orally administered drug designed to inhibit the activity of proteins called KIT and PDGFRα. KIT and PDGFRα are proteins that are mutated or abnormally active in variety of cancer cell types; when mutated, these proteins can increase tumor cell proliferation and resistance to chemotherapy.
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Ependymoma
Medulloblastoma
Brainstem Glioma
Diffuse Midline Glioma
This phase I clinical trial will evaluate the safety and tolerability of a single tumor injection of Ad-RTS-hIL-12 given with veledimex, for pediatric patients with brain tumors.
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Ependymoma
Medulloblastoma
Summary
The purpose of this Phase I/II clinical trial is to evaluate the dosage, safety and efficacy of pembrolizumab in treating pediatric participants with any of the following types of cancer:
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Subependymal giant cell astrocytoma (grade I)
Medulloblastoma
Choroid Plexus Tumors
The purpose of this Phase I clinical trial is to evaluate the safety and efficacy of the drug ramucirumab, in treating children with recurrent or refractory solid tumors, including CNS tumors.
Conditions
Glioma
Astrocytoma
Diffuse astrocytoma (grade II)
Oligodendroglioma
This clinical trial evaluates the safety and feasibility of IMA950 (a vaccine-based immunotherapy) in combination with varlilumab (an antibody-based immunotherapy) in patients with newly diagnosed or recurrent low-grade glioma (grade II).
Conditions
Glioma
Astrocytoma
Brainstem Glioma
Diffuse Midline Glioma
This phase I clinical trial studies the side effects and best dose of adavosertib in combination with radiation therapy in treating children and young adults with newly diagnosed DIPG.
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
Anaplastic astrocytoma (grade III)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I clinical trial will evaluate the safety, efficacy and clinical activity of BGB-290 in combination with temozolomide, for treating adolescents and young adults with IDH1/2-mutant glioma (grades I-IV).
Conditions
Glioma
Astrocytoma
Diffuse Midline Glioma
Brainstem Glioma
This Phase I clinical trial will assess the safety and preliminary efficacy of delivering nal-IRI (a specialized formulation of irinotecan, a chemotherapy drug) directly into the brain through convection enhanced delivery, in treating children with newly diagnosed DIPG.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
Ependymoma
Oligodendroglioma
This pilot trial will evaluate an individualized treatment approach for children and young adults with high-grade glioma, using proteomic, transcriptomic, and genomic profiling to provide a personalized treatment plan.
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
This clinical trial will evaluate the efficacy of MDNA55 in treating patients with recurrent glioblastoma. MDNA55 will be administered during a minimally invasive surgery, using convection-enhanced delivery.
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
This phase I trial will evaluate an individualized treatment approach, based on the results of the UCSF 500 Cancer Gene Panel, for patients with surgically resectable recurrent glioblastoma.